BioCryst Pharmaceuticals, Inc. (BCRX) Reports In-Line Q4 EPS
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $4.15 -1.43%
EPS Growth %: +25.0%
Financial Fact:
Total revenues: 7.76M
Today's EPS Names:
FRSB, DGICA, UXIN, More
EPS Growth %: +25.0%
Financial Fact:
Total revenues: 7.76M
Today's EPS Names:
FRSB, DGICA, UXIN, More
Join SI Premium – FREE
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) reported Q4 EPS of ($0.29), in-line with the analyst estimate of ($0.29). Revenue for the quarter came in at $5.2 million versus the consensus estimate of $7.34 million.
BioCryst Pharmaceuticals, Inc. sees FY2012 EPS of (n/a). BioCryst Pharmaceuticals, Inc. sees FY2012 revenue of $5 million.
For earnings history and earnings-related data on BioCryst Pharmaceuticals, Inc. (BCRX) click here.
BioCryst Pharmaceuticals, Inc. sees FY2012 EPS of (n/a). BioCryst Pharmaceuticals, Inc. sees FY2012 revenue of $5 million.
For earnings history and earnings-related data on BioCryst Pharmaceuticals, Inc. (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Airbus revenue rises, delivers 142 commercial aircraft in Q1
- First Resource Bank (FRSB) Tops Q1 EPS by 43c
- CEMEX, S.A.B. de C.V. (CX) Tops Q1 EPS by 5c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
